Skip to content

Serotonin: all studies

Page 178 of 400: studies 1,771 to 1,780 of 3,999, newest first. Back to the serotonin overview

Research

Preclinical Comparison of DMT and 5-MeO-DMT Reveals Behavioral Dissociation, Distinct TrkB Activation and Differential Plasticity Profiles

bioRxiv (Cold Spring Harbor Laboratory) August 12, 2026 Orr Shahar, Alexander Botvinnik, Masha Chaykin et al. preprint

Abstract N, N-dimethyltryptamine (DMT) and 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) are structurally related tryptamine psychedelics with emerging therapeutic potential, yet their comparative acute pharmacology and longer-term neuroplastic effects remain incompletely defined. Here we show that DMT produces a bell-shaped dose–response curve in the mouse head-twitch response (HTR) assay,...

Direct anti-inflammatory actions of N,N -dimethyltryptamine on microglia are revealed by proteomic profiling and receptor pharmacology

bioRxiv (Cold Spring Harbor Laboratory) August 11, 2026 István Pesti, Ágnes Bessenyei, Rita Frank et al. preprint

ABSTRACT N,N -dimethyltryptamine (DMT) is an endogenous psychedelic tryptamine that has recently emerged as a promising therapeutic candidate for acute ischemic stroke. Although DMT consistently reduces infarct size, attenuates neuroinflammation, and improves functional outcome in experimental stroke, the cellular and receptor mechanisms underlying these effects remain poorly understood....

Mapping basal ganglia circuitry in altered states of consciousness: from pathology to pharmacology.

Brain August 7, 2026 Dorottya Szocs, Andrea I. Luppi, Peter Coppola et al.

The precise neuromodulatory mechanisms underlying consciousness and its disorders, despite growing evidence in both animals and humans, remain poorly understood at the subcortical level. The basal ganglia, a key component of the cortico-basal ganglia-thalamo-cortical loop, are known to play a crucial role in mediating consciousness and behavioural responsiveness to the environment. Here, we...

DOI: 10.1093/brain/awag272 (opens in new tab) Full text (opens in new tab) Basal ganglia nuclei Disorders of consciousness Neurotransmitters and transporters Resting-State FMRI +2

O USO DA PSILOCIBINA EM CONTEXTO TERAPÊUTICO PARA O TRATAMENTO DA COMPULSÃO POR NICOTINA SOB A PERSPECTIVA DA NEUROPSICOLOGIA

Asclepius International Journal of Scientific Health Science August 7, 2026 Arthur Gomes Ferreira

A dependência da nicotina representa um dos principais desafios da saúde pública mundial, sendo responsável por elevadas taxas de morbimortalidade e associada ao desenvolvimento de doenças cardiovasculares, respiratórias e neoplásicas. Embora existam diferentes estratégias terapêuticas para a cessação do tabagismo, as elevadas taxas de recaída evidenciam a necessidade de novas abordagens...

Multidimensional characterization of the physiological and behavioral effects of TCB-2 in mice

bioRxiv August 6, 2026 Mizuki Yamamoto, Hiroto Inoue, Kazuko Hayashi et al. preprint

Background and Purpose Serotonergic psychedelics affect behavior and physiology, but the relationships among these effects remain poorly understood. In rodents, the head-twitch response is used as a measure of psychedelic-like activity, yet it does not capture changes in physiological state or the performance of learned behaviors. Here, we investigated the acute effects of the 5-HT2A receptor...

The molecular and neurochemical basis of altered intrinsic neural timescales in major depressive disorder: a multimodal imaging-transcriptomic investigation of esketamine and sertraline treatment

BMC Psychiatry August 5, 2026 Xiang Liu, Yuanzhi He, Lifeng Li et al.

Abstract Introduction Major depressive disorder (MDD) is characterized by dysfunction in higher-order cortical regions involved in emotional and cognitive processes; however, its neurobiological basis remains unclear. Pharmacological treatments, including esketamine and sertraline, produce rapid antidepressant effects. We investigated the local intrinsic neural dynamics underlying these...

Blinding Integrity and Psychedelic Drug Trials

JAMA Psychiatry August 5, 2026 Michael Elliott, Olga Chernoloz

To the Editor In JAMA Psychiatry, Cubała et al. report that inhaled mebufotenin (GH001) reduced depression severity by 15.5 points more than placebo on the Montgomery-Åsberg Depression Rating Scale (MADRS) at 1 week, with 57.5% of patients achieving remission vs 0% in the placebo group. The effect size (d = −2.0) overwhelmingly surpasses those of selective serotonin reuptake inhibitors,...

Ultrasonic potentiation of ketamine neuromodulation.

bioRxiv : the preprint server for biology August 4, 2026 Kanchan Sinha Roy, Payton Martinez, Sedona N. Ewbank et al. preprint

The psychiatric utility of ketamine is limited by its dissociative and systemic side effects. Recently, to enable precision ketamine pharmacotherapy, we introduced SonoKet, ketamine-loaded acoustically activatable liposomes that enable focused ultrasound (FUS)-targeted ketamine delivery to millimeter-sized brain regions. In initial studies, we observed that SonoKet uncaging targeted ketamine to...

Psychedelics and women’s mental health: the effects of female sex hormones on psychedelics’ efficacy and tolerability

Molecular Psychiatry August 4, 2026 Kim P. C. Kuypers, Natasha L. Mason, Aurelie Carlier et al.

Women experience a disproportionate burden of affective and stress-related disorders, with symptom variability shaped by endocrine transitions across the menstrual cycle, pregnancy, postpartum, and menopause. Although psychedelic-assisted therapies are increasingly investigated for these conditions, hormonal state represents a largely unaccounted determinant of variability in exposure,...